We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

This study has been terminated.
(Lack of participants)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00585585
First Posted: January 3, 2008
Last Update Posted: July 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Erik Nelson, University of Cincinnati
  Purpose
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.

Condition Intervention Phase
Recurrent Major Depressive Disorder With Atypical Features Drug: betahistine dihydrochloride Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

Further study details as provided by Erik Nelson, University of Cincinnati:

Primary Outcome Measures:
  • Maximum Tolerable Dose of Betahistine Dihydrochloride in mg [ Time Frame: 7 weeks ]
    The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.


Enrollment: 1
Study Start Date: July 2007
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Betahistine dihydrochloride
Oral betahistine dihydrochloride; daily dose 50-300 mg
Drug: betahistine dihydrochloride
oral, 50-300 mg, daily
Other Name: SERC

Detailed Description:
All patients will start taking 50 mg of betahistine dihydrochloride on treatment day 1 (after baseline visit). Starting on day 4, the daily dose will be increased by adding a 50 mg dose. If tolerated, the daily dose will be titrated to 200 mg. At the end of week 3, the dose will be titrated to 300 mg.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have signed written informed consent
  2. Be male and/or female outpatients 18 65 years of age, inclusive
  3. For women: must be surgically sterile, 2 years postmenopausal, or, if they have childbearing potential, using a medically accepted method of birth control and agree to continue use of this method for at least 30 days after the last dose of study drug (i.e., barrier method with spermicide, steroidal contraceptive or intrauterine device [IUD])
  4. Meet DSM IV1 criteria for major depressive episode (unipolar), with atypical features
  5. Have a score of 20 or greater on the Hamilton Depression Rating, 28-item version (HAM-D-28)
  6. Have a complete medical and psychiatric history, physical examination, laboratory evaluation, and ECG before study entry.
  7. Have baseline laboratory values and ECG that are normal, or abnormalities that are clinically insignificant

Exclusion Criteria:

  1. Have significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination
  2. Have a history of peptic ulcer disease
  3. Have a history of severe asthma
  4. Have a current diagnosis of pheochromocytoma
  5. Are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit)
  6. Meet criteria for DSM IV1 psychoactive substance abuse or dependence in the past month
  7. Have a history of a psychotic disorder
  8. Use any medications that, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with betahistine dihydrochloride including centrally acting antihistaminic agents
  9. Have a history of hypersensitivity to betahistine dihydrochloride
  10. Exhibit, or suggestion that they may display, behavior that will not be conducive to the study procedures
  11. Are at significant risk of suicide as indicated by a score of 3 or greater on item number 11 on the HAM-D 28
  12. Have received any investigational product within 28 days of Screening
  13. Have used any antidepressant within 7 days of Screening (14 days for MAOIs; 21 days for fluoxetine)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00585585


Locations
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267-0559
Sponsors and Collaborators
University of Cincinnati
Investigators
Principal Investigator: Erik Nelson, MD University of Cincinnati
  More Information

Responsible Party: Erik Nelson, Adjunct Associate Professor, University of Cincinnati
ClinicalTrials.gov Identifier: NCT00585585     History of Changes
Other Study ID Numbers: Nelson #1
First Submitted: December 28, 2007
First Posted: January 3, 2008
Results First Submitted: March 8, 2011
Results First Posted: July 25, 2017
Last Update Posted: July 25, 2017
Last Verified: July 2017

Keywords provided by Erik Nelson, University of Cincinnati:
Depression
Betahistine Dihydrochloride

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Recurrence
Behavioral Symptoms
Mood Disorders
Mental Disorders
Disease Attributes
Pathologic Processes
Betahistine
Vasodilator Agents
Histamine Agonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs